Slide 1: Q1 2023 Results
Q1 2023 Results Conference call and webcast for investors and analysts 27 April 2023
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: This document contains certain forward-looking statements wit
Slide 3: Conference call agenda
Q1 2023 results Conference call agenda CEO Opening Remarks Pascal Soriot Chief Executive Officer Financial Results Aradhana Sarin Chief Financial Officer Oncology Dave Fredrickson Susan Galbraith EVP, Oncology Business EVP, Oncology R&D BioPharmaceuticals Ruud Dobber Mene Pangalos EVP, BioPharmaceut
Slide 4: CEO Opening Remarks
CEO Opening Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 5: Q1 2023 – 15% growth from ex-COVID-19 medicines
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Q1 2023 – 15% growth from ex-COVID-19 medicines1 Stable Total Revenue, reiterating FY 2023 guidance Growth in Oncology, CVRM, R&I and Rare Disease offset decline in COVID-19 medicines Total Revenue | s
Slide 6: Q1 2023 – broad-based, diverse source of business
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Q1 2023 – broad-based, diverse source of business Q1 2023 | % Total Revenue by therapy area Strong growth across Oncology, CVRM, R&I and Oncology CVRM R&I V&I Rare Disease Other Rare Disease 38% 24% 15
Slide 7: Accelerating our late-stage pipeline
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Accelerating our late-stage pipeline Potential to initiate 30 Phase III trials, with six dosed to-date in 20231 Dato-DXd Dato-DXd Tezspire AZD3152 camizestrant Ultomiris AVANZAR2 TROPION-Lung072 CROSSI
Slide 8: Financial Results
Financial Results Aradhana Sarin CHIEF FINANCIAL OFFICER
Slide 9: Q1 2023 – Reported profit and loss
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Q1 2023 – Reported profit and loss Q1 2023 CER change % Total $m % Revenue Total Revenue 10,879 - 100 - Product Sales 10,566 1 97 - Alliance Revenue 286 90 3 - Collaboration Revenue 27 (89) - Gross mar
Slide 10: Q1 2023 – Core profit and loss
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Q1 2023 – Core profit and loss Q1 2023 CER change % Total $m % Revenue Total Revenue 10,879 - 100 - Product Sales 10,566 1 97 - Alliance Revenue 286 90 3 - Collaboration Revenue 27 (89) - Gross margin
Slide 11: Cash Flow, Net Debt and 2023 Financial Guidance
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Cash Flow, Net Debt and 2023 Financial Guidance Continued EBITDA improvement Net Debt bridge Reiterating 2023 Guidance $bn 3.0 25.1 22.9 2.0 0.1 Total Revenue 0.2 3.1 • Excluding COVID-19 medicines: lo
Slide 12: Artificial Intelligence at AstraZeneca
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Artificial Intelligence at AstraZeneca Leadership in AI is transforming the way we work and pace of innovation AI is embedded across our organisation R&D • OPERATIONS • COMMERCIAL 400+ Drug discovery a
Slide 13: Oncology
Oncology Dave Fredrickson ONCOLOGY BUSINESS Susan Galbraith ONCOLOGY R&D
Slide 14: Oncology – Q1 2023
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – Q1 2023 19% Total Revenue growth driven by differentiated portfolio and new indication launches Oncology Q1 2023: key dynamics Q1 2023 $4.1bn, +19% at CER 4,500 • Tagrisso +15% CER, driven b
Slide 15: Oncology
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030 resectable Stg. I-III unresectable Stg. I-II Stg. III 1L metastatic 2L+ Leading the future of Est. epi (G7) ~2
Slide 16: Oncology – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – R&D highlights Moving into earlier lines of lung cancer with highest potential for cure AEGEAN: updated pCR and interim EFS ADAURA: final OS Imfinzi-based treatment before and adjuvant Tagri
Slide 17: Oncology – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – R&D highlights AACR demonstrates harnessing of in-house capabilities to build early-stage pipeline Preclinical data for three AstraZeneca First clinical data for CAR-T therapy in-house devel
Slide 18: BioPharmaceuticals
BioPharmaceuticals Ruud Dobber BIOPHARMACEUTICALS BUSINESS Mene Pangalos BIOPHARMACEUTICALS R&D
Slide 19: BioPharmaceuticals – Q1 2023
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals – Q1 2023 Increasing momentum across CVRM and R&I CVRM R&I V&I Q1 2023 $2.6bn, +22% at CER Q1 2023 $1.6bn, +8% at CER Q1 2023 $355m, -79% at CER 3,000 1,800 2,500 1,600 2,500 1,400 2
Slide 20: BioPharmaceuticals – Q1 2023
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals – Q1 2023 Key medicines driving R&I growth Building launch momentum in R&I +46% growth in Q1 from key R&I medicines Total Revenue ($m) Total Revenue ($m) 54 Fasenra • Tezspire • Saph
Slide 21: BioPharmaceuticals – R&D highlights
BioPharmaceuticals – R&D highlights Leading respiratory portfolio across asthma and COPD Inhaled maintenance therapy Novel oral / inhaled add-ons Novel systemic biologics 35m patients1 6m patients1 2m patients1 Airsupra Novel atuliflapon Tezspire (ICS/SABA) oral (FLAP inhibitor) Phase II data: 2024
Slide 22: BioPharmaceuticals – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals – R&D highlights Congress highlights at AAN and ECCMID eplontersen in ATTRv-PN AZD3152 NEURO-TTRansform Phase III final analysis (66 wk) long-acting COVID-19 antibody -14.5% -81.2% 0
Slide 23: AI in R&D
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks AI in R&D Accelerating the time to deliver clinical leads DRUG DISCOVERY & DEVELOPMENT | reinventing the traditional drug discovery process Knowledge graphs | Accelerating discovery speed | small and l
Slide 24: Rare Disease
Rare Disease Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION
Slide 25: Rare Disease – Q1 2023
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Rare Disease – Q1 2023 Accelerated conversion in C5, continued strength beyond complement Rare Disease Q1 2023: key dynamics Q1 2023 $1.9bn, +14% at CER 2,000 Durable C5 Franchise growth 1,800 1,600 •
Slide 26: Rare Disease – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Rare Disease – R&D highlights Pioneering in rare neurology to improve patient outcomes Soliris gMG registry1 gefurulimab (ALXN1720) oral corticosteroid usage decreased over time pipeline expansion to f
Slide 27: Rare Disease – R&D
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Rare Disease – R&D Industry-leading Factor D portfolio Factor D inhibition Factor D portfolio more tractable target, lower circulating concentration in plasma novel small molecule assets with high affi
Slide 28: CEO Closing Remarks
CEO Closing Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 29: AstraZeneca – Q1 2023
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks AstraZeneca – Q1 2023 Accelerating pipeline momentum, disciplined investment fuels industry-leading growth Pipeline advances in 2023 Sustainable, long-term growth with 18 Phase III read-outs anticipate
Slide 30: Question & Answer Session
Question & Answer Session Pascal Soriot Aradhana Sarin Marc Dunoyer EX EC UT IVE DIREC T O R & EX EC UT IVE DIREC T O R & C H IEF EX EC UT IVE O F F IC ER, C H IEF EX EC UT IVE O F F IC ER C H IEF F IN AN C IAL O F F IC ER AL EX IO N Susan Galbraith Dave Fredrickson Mene Pangalos EX EC UT IVE VIC E
Slide 31: Appendix
Appendix § Pipeline Highlights since Q4/FY2022 results § ESG & Corporate Sustainability § Oncology landscapes: breast and lung § Emerging Markets § Key Performance by Therapy Area
Slide 32: Delivering on science-led innovation
A P P E N D I X | Pipeline Highlights Delivering on science-led innovation Selected key pipeline highlights since Q4/FY 2022 results Oncology BioPharmaceuticals Rare Disease 5 regulatory approvals in major markets, including: Imfinzi +/- Imjudo (EU) Calquence (EU) non-small cell lung cancer (1st-lin
Slide 33: 2022 Sustainability highlights
A P P E N D I X | ESG & Corporate Sustainability 2022 Sustainability highlights Progress on our overall Access to Healthcare Environmental protection Ethics and transparency strategy includes: 14 126,684 59.3% 49.5% public and private sector organisations healthcare workers and others trained1 reduc
Slide 34: Emerging Markets – Q1 2023
A P P E N D I X | Emerging Markets Emerging Markets – Q1 2023 Total Revenue +1% at CER to $3.2bn. +22% at CER excluding COVID-19 medicines 4,000 3,500 3,000 2,500 Total Revenue ($m) 2,000 1,500 1,000 500 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2021 2022 2023 China Emerging Markets ex. China COVID-19 medicines 34
Slide 35: Oncology
A P P E N D I X | Q1 2023 Product Performance Oncology Tagrisso Imfinzi 15% growth at CER to $1,424m 56% growth at CER to $900m 1,600 1,000 1,400 900 1,200 800 Total Revenue ($m) 700 Total Revenue ($m) 1,000 600 800 500 600 400 400 300 200 200 100 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3
Slide 36: Oncology – Lynparza
A P P E N D I X | Q1 2023 Product Performance Oncology Lynparza Lynparza 14% decrease at CER to $651m Collaboration Revenue: $3.8bn recorded cumulative, $3.9bn future potential 800 600 700 600 Sales ($m) 500 400 Collaboration Revenue ($m) Total Revenue 400 Product 300 200 200 100 0 0 Q1 Q2 Q3 Q4 Q1
Slide 37: Oncology
A P P E N D I X | Q1 2023 Product Performance Oncology Calquence Enhertu 31% growth at CER to $532m >3x growth at CER to $257m 700 300 600 250 500 Total Revenue ($m) Total Revenue ($m) 200 400 150 300 100 200 100 50 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2021 2022 2023 2021 2022 2
Slide 38: BioPharmaceuticals: Cardiovascular, Renal & Metabolism
A P P E N D I X | Q1 2023 Product Performance BioPharmaceuticals: Cardiovascular, Renal & Metabolism Farxiga Brilinta Lokelma 39% growth at CER to $1,324m 5% growth at CER to $334m 64% growth at CER to $98m 1,400 400 120 1,200 350 100 300 1,000 Total Revenue ($m) Total Revenue ($m) Total Revenue ($m
Slide 39: BioPharmaceuticals: Respiratory & Immunology
A P P E N D I X | Q1 2023 Product Performance BioPharmaceuticals: Respiratory & Immunology Fasenra Breztri Tezspire 13% growth at CER to $338m 73% growth at CER to $144m 32% sequential growth at CER to $54m 450 160 60 400 140 50 350 120 Total Revenue ($m) Total Revenue ($m) Total Revenue ($m) 300 40
Slide 40: BioPharmaceuticals: Respiratory & Immunology
A P P E N D I X | Q1 2023 Product Performance BioPharmaceuticals: Respiratory & Immunology Symbicort Pulmicort 7% growth at CER to $688m 9% growth at CER to $221m 800 350 700 300 600 250 Total Revenue ($m) Total Revenue ($m) 500 200 400 150 300 100 200 100 50 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3
Slide 41: Rare Disease
A P P E N D I X | Q1 2023 Product Performance Rare Disease Soliris Ultomiris Strensiq 13% decrease at CER to $834m 61% growth at CER to $651m 28% growth at CER to $262m 1,200 700 300 600 250 1,000 500 Total Revenue ($m) Total Revenue ($m) Total Revenue ($m) 800 200 400 600 150 300 400 100 200 200 10